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Cardiac muscle Ca2+ signaling and excitation-contraction coupling rely on a relatively small 
Ca2+ influx via voltage-dependent L-type Ca2+ channels, which is amplified by a severalfold 
larger Ca2+ release from the sarcoplasmic reticulum (SR) via ryanodine receptor Ca2+ 
release channels (RyRs). The Ca2+-induced Ca2+ release mechanism (CICR) is driving this 
signal amplification. Besides the RyRs, inositol trisphosphate receptors (IP3Rs), a type of 
Ca2+ release channels with many similarities to the RyRs, are also present in 
cardiomyocytes. But they are vastly outnumbered by the RyRs (ratios of 1:50 to 1:100). 
While IP3Rs seem important and more abundant during early cardiac development, their 
relative expression level declines later, as the SR matures and the number of RyRs 
increases. Why mother nature is perpetuating the presence of the IP3Rs at a low density in 
cardiac muscle has remained a mystery. Several hypotheses have been tested in 
experimental studies, but the puzzle remains incompletely solved and the role(s) of the 
IP3Rs is not yet clearly defined. In cardiomyocytes, particularly in atrial cells where 
InsP3Rs are more abundant, a modulatory function of InsP3Rs on CICR has been 
recognized (Mackenzie et al., 2002). IP3Rs may indeed participate in Ca2+ signaling, 
secondary to acute or chronic stimulation of membrane receptors linked to the 
phospholipase C (PLC) - IP3 signaling pathways, such as endothelin (ET) or angiotensin 
(AT) II receptors (Horn et al., 2013). Recently, it has been found that IP3Rs located in the 
nuclear envelope are involved in excitation-transcription coupling, thereby participating in 
the control of gene expression programs. During several pathological conditions, chronic 
activation of these pathways may engage in cell growth, hypertrophy and the initiation of 
dedifferentiating gene programs (Nakayama et al., 2010). One notable cardiac condition in 
which overexpression of IP3Rs has been observed is the development of cardiac 
hypertrophy and failure (Harzheim et al., 2009). In these and related diseases, IP3Rs could 
represent a key element of a slowly developing positive feed-back loop, whereby their 
maintained activation (in the nucleus) leads to an increase of their own cellular expression 
via excitation-transcription coupling. How potential Ca2+ signaling complications arising 
from this constellation could be avoided by spatially targeting the IP3R expression and by 
finely tuning their activity can be conceptualized based on findings published in the 
present issue of The Journal of Physiology (Hohendanner et al., 2014). 
 
In an elegant functional study a wide array of state-of-the art methods was combined (e.g. 
IP3 measurements with FIRE, an IP3 affinity trap, photorelease of IP3, etc.) to define how 
IP3R and RyR mediated Ca2+ release orchestrates Ca2+ signaling in atrial and ventricular 
myocytes isolated from normal and heart-failure (HF) rabbits. The first astonishing finding 
was that in the absence of any IP3 generating stimuli (i.e. at basal cellular IP3 levels) and 
in sharp contrast to the behavior of ventricular myocytes, the Ca2+ transients recorded 
from HF atrial myocytes were markedly larger than those from control cells. More detailed 
analysis of this unexpected observation revealed that it was predominantly due to larger 
and faster centripetal Ca2+ signal propagation, mostly depending on boosted Ca2+ release 
  
via IP3Rs located throughout the cell, with a possible contribution by reduced mitochondrial 
Ca2+ uptake. The next surprising observation was made when IP3 levels were 
experimentally elevated above basal, as it might occur in-vivo (e.g. by photolysis of caged 
IP3 or by ATII). While normal atrial myocytes responded with a slightly increased Ca2+ 
transient amplitude, the HF cells exhibited dramatically reduced Ca2+ signals combined 
with slowly rising diastolic Ca2+ concentrations. The reduced amplitudes were particularly 
evident after prolonged exposure to elevated IP3 levels, and appeared to be caused by a 
larger SR Ca2+ leak, manifest as a higher frequency of Ca2+ puffs and arrhythmogenic 
Ca2+ waves, and a corresponding decline of intra SR Ca2+. 
 
The strikingly divergent behavior of the atrial myocyte Ca2+ signaling system under 
conditions of constitutively low versus stimulated IP3 concentrations is dazzling. These 
results reveal a new dimension of atrial myocyte Ca2+ signaling modulation by IP3. While in 
HF atrial cells the overexpressed IP3Rs may contribute to their inotropy at basal IP3 levels, 
acute stimulation of IP3 generating pathways may be pro-arrhythmogenic (by increasing 
the propensity for Ca2+ waves) and in the long run curtail atrial Ca2+ signaling, by 
maintaining an SR Ca2+ leak ultimately lowering its Ca2+ load. 
 
It is well established that patients with HF have elevated levels of circulating ATII. 
Therefore, the findings of the present study are potentially therapeutically relevant, both for 
the atrial mechanical performance (atrial kick) and for atrial arrhythmias. However, the 
effects of cytosolic IP3 seem to be vastly different, if not opposite, in atrial myocytes after 
remodeling of their Ca2+ signaling during HF. Thus, it will be crucial to define the role of IP3 
not only in isolated cell preparations, but to translate these findings to the more complex 
situation and neurohumoral environment of the organ and even patient, where cytosolic 
IP3 levels may vary. Such studies seem to be needed to obtain an integrated view of atrial 
Ca2+ signaling during HF with all of its complexities. This knowledge would appear to be a 
important pre-requisite to design mechanisms based therapeutical strategies. 
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